PT3946276T - Composição de libertação sustentada compreendendo tapentadol e seu método de preparação - Google Patents
Composição de libertação sustentada compreendendo tapentadol e seu método de preparaçãoInfo
- Publication number
- PT3946276T PT3946276T PT207211467T PT20721146T PT3946276T PT 3946276 T PT3946276 T PT 3946276T PT 207211467 T PT207211467 T PT 207211467T PT 20721146 T PT20721146 T PT 20721146T PT 3946276 T PT3946276 T PT 3946276T
- Authority
- PT
- Portugal
- Prior art keywords
- tapentadol
- preparation
- sustained release
- release composition
- composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title 1
- 229960005126 tapentadol Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20190100148A GR1009791B (el) | 2019-03-26 | 2019-03-26 | Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει ταπενταδολη και μεθοδος παρασκευης αυτου |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3946276T true PT3946276T (pt) | 2024-03-15 |
Family
ID=70456723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207211467T PT3946276T (pt) | 2019-03-26 | 2020-03-23 | Composição de libertação sustentada compreendendo tapentadol e seu método de preparação |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220168241A1 (pt) |
| EP (1) | EP3946276B1 (pt) |
| AU (1) | AU2020246867A1 (pt) |
| CA (1) | CA3134730A1 (pt) |
| DK (1) | DK3946276T3 (pt) |
| FI (1) | FI3946276T3 (pt) |
| GR (1) | GR1009791B (pt) |
| LT (1) | LT3946276T (pt) |
| PT (1) | PT3946276T (pt) |
| WO (1) | WO2020192970A1 (pt) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| ES2612032T3 (es) | 2007-06-04 | 2017-05-11 | Shear/Kershman Laboratories, Inc. | Formas farmacéuticas orales basadas en lípidos inviolables para agonistas opiáceos |
| MX2012000317A (es) * | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
| AR082167A1 (es) * | 2010-07-14 | 2012-11-14 | Gruenenthal Gmbh | Formas de dosificacion gastrorretentivas |
| FR2979242A1 (fr) | 2011-08-29 | 2013-03-01 | Sanofi Sa | Comprime contre l'usage abusif, a base de paracetamol et d'oxycodone |
| ES2851175T3 (es) | 2013-02-05 | 2021-09-03 | Purdue Pharma Lp | Formulaciones farmacéuticas resistentes a manipulación |
| BR112016000194A8 (pt) * | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
| CA3039951A1 (en) * | 2015-10-21 | 2017-04-27 | Mec Device Pharma International Llc | Compositions for deterring abuse of pharmaceutical products and alcohol |
| US20180303757A1 (en) * | 2015-10-23 | 2018-10-25 | Kashiv Pharma Llc | Enhanced abuse-deterrent formulations of oxycodone |
-
2019
- 2019-03-26 GR GR20190100148A patent/GR1009791B/el active IP Right Grant
-
2020
- 2020-03-23 DK DK20721146.7T patent/DK3946276T3/da active
- 2020-03-23 LT LTEPPCT/EP2020/025140T patent/LT3946276T/lt unknown
- 2020-03-23 US US17/442,214 patent/US20220168241A1/en active Pending
- 2020-03-23 WO PCT/EP2020/025140 patent/WO2020192970A1/en active Application Filing
- 2020-03-23 PT PT207211467T patent/PT3946276T/pt unknown
- 2020-03-23 CA CA3134730A patent/CA3134730A1/en active Pending
- 2020-03-23 AU AU2020246867A patent/AU2020246867A1/en active Pending
- 2020-03-23 FI FIEP20721146.7T patent/FI3946276T3/fi active
- 2020-03-23 EP EP20721146.7A patent/EP3946276B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3946276B1 (en) | 2023-12-13 |
| GR1009791B (el) | 2020-08-03 |
| AU2020246867A1 (en) | 2021-11-18 |
| DK3946276T3 (da) | 2024-03-18 |
| EP3946276A1 (en) | 2022-02-09 |
| FI3946276T3 (fi) | 2024-03-15 |
| WO2020192970A1 (en) | 2020-10-01 |
| LT3946276T (lt) | 2024-04-10 |
| CA3134730A1 (en) | 2020-10-01 |
| US20220168241A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261176B2 (en) | Preparations for the controlled release of active ingredients and methods for their preparation | |
| EP3576764A4 (en) | KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USE | |
| SI3675816T1 (sl) | Anestetični sestavki z zadržanim sproščanjem in postopki za njihovo pripravo | |
| SG11202009315WA (en) | Formulation and method of preparation | |
| IL288372A (en) | Modified release preparation and uses thereof | |
| IL288044A (en) | Preparations containing ephardin or ephardin salt and methods for their preparation and use | |
| IL290185A (en) | Crystalline forms of risdiplam and their preparation process | |
| EP4060022A4 (en) | METHOD FOR PREPARING TONSILLARY ORGANOIDS AND ITS USE | |
| IL273690A (en) | Gingivitis vaccine and related preparations and methods of using it | |
| FI3946276T3 (fi) | Tapentadolia käsittävä pitkävaikutteinen koostumus ja menetelmä sen valmistamiseksi | |
| ZA201902044B (en) | Sustained release composition comprising tapentadol and method of preparation thereof | |
| PL3692127T3 (pl) | Substancje pro-zapachowe i sposób ich wytwarzania | |
| FI3941443T3 (fi) | Tapentadolioksalaattia käsittävä pitkävaikutteinen koostumus ja menetelmä sen valmistamiseksi | |
| ZA201902045B (en) | Sustained release composition comprising tapentadol oxalate and method of preparation thereof | |
| IL286713A (en) | Liposomal formulations and methods for their use and preparation | |
| EP4081233A4 (en) | COMPOSITION AND MANUFACTURING PROCESSES | |
| ZA202007392B (en) | Concrete release agent and preparation method therefor | |
| SG11202011121UA (en) | Dantrolene formulations and methods of their use | |
| PL3692126T3 (pl) | Substancje pro-zapachowe i sposób ich wytwarzania | |
| GB201810395D0 (en) | Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation | |
| GB201902017D0 (en) | Methods of preparing and using perfume compositions | |
| EP3727347A4 (en) | LONG-RELEASE MIDODRINE HYDROCHLORIDE COMPOSITIONS AND METHODS OF USE | |
| ZA202203368B (en) | Immunogenic compositions against enteric diseases and methods for its preparation thereof | |
| EP3731931A4 (en) | FESOTERODINE MODIFIED RELEASE FORMULATIONS | |
| ZA201905253B (en) | Pharmaceutical composition comprising naltrexone microspheres and method of preparation thereof |